Astellas teams up with UK biotech Mogrify on hearing loss project
Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused […]
Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused […]
Satellite Bio has emerged from stealth with technology for bioengineering tissue to restore organ function. The regenerative medicine startup, based on research from MIT and […]
ProKidney is going public in a SPAC merger that infuses the biotech with $825 million for Phase 3 tests and manufacturing of its autologous cell […]
As in previous years, cancer products topped the list of new FDA-approved therapies in 2021. But the list of drug approvals is notable for other […]
In the latest episode of the podcast Dominic Tyer speaks with Dr Maria Ines ‘Mari’ Mitrani, chief science officer at the clinical-stage biopharmaceutical company Organicell Regenerative […]
Mallinckrodt Pharmaceuticals received FDA approval for its engineered skin product, StrataGraft, a treatment for serious thermal burns. The product is the latest to be reviewed […]
Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed. The Danish drugmaker […]
Regenerative medicine might someday provide replacement organs for transplant patients. But Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine, explained how the […]
Scientists at The Ohio State University are developing a cell therapy intended to regrow brain tissue damaged from ischemic stroke. Results from a study in […]
Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked […]
Shots: SMA Foundation and PTC will provide an initial investment of up to $60M in research to discover & develop regenerative treatments in neuromuscular diseases […]
Humacyte is going public via a SPAC merger that infuses it with $255 million for its regenerative medicine pipeline. The biotech’s technology produces universally implantable […]
Copyright © 2024 | WordPress Theme by MH Themes